used AZA to treat 231Br brain metastasis breast cancer cells and found that K18 mRNA levels were significantly increased dose dependently, and there was no difference in DNA sequences between 231Br and 231 situ breast cancer cells (100). Here, KRT18 is linked to breast carcinoma.